Delft Instruments suffers $21 million loss
This article was originally published in Clinica
Delft Instruments claims that an unexpected dearth of orders for radiotherapy equipment and software from its subsidiary Nucletron, will mean a net loss of around $21 million last year.
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.